The BASE Facility has partnered with Oxford Nanopore Technology to develop nanopore sequencing methods to analyse mRNA vaccine quality control.
Sartorius has partnered with the BASE Facility to co-develop protocols and methods to improve the quality and yield of mRNA synthesis.
The BASE facility partners with DNA Script to use Enzymatic DNA Synthesis Technology in mRNA vaccine manufacture as part of the DNA Scriptors Early Access Program.
BASE is supported by the National Collaborative Research Infrastructure Strategy (NCRIS)
TIA can support the development of your mRNA candidates as part of the Pipeline Accelerator voucher scheme. Successful applicants receive up to $50,000 matching funds to develop mRNA drug candidates with BASE research and manufacturing services.